Johannes Poon

Mr. Poon’s experience includes advising:

• Mothercare plc, baby and maternity retailer, on its £32.5 million placing and open offer on the main market of the London Stock Exchange*
• PureTech Health plc, a Boston-based science-driven company, on its £363.6 million IPO admission to premium listing and to trading on the main market of the London Stock Exchange*
• Allied Minds plc, a Boston-based technology commercialisation company, on its £405.3 million IPO admission to premium listing and to trading on the main market of the London Stock Exchange*
• (As UK securities counsel) HutchMed, a China-based, globally-focused healthcare group, on its US$100 million listing of American Depository Shares on the Nasdaq Global Select Market. Advising (as UK securities counsel) HutchMed, a China-based, globally-focused healthcare group, on its US$110 million underwritten public offering of American Depositary Shares on the Nasdaq Global Select Market*
• (As UK securities counsel) HutchMed, a China-based, globally-focused healthcare group, on its PIPE sale of US$100 million of shares via a private placement to Canada Pension Plan Investment Board*
• (As UK securities counsel) HutchMed, a China-based, globally-focused healthcare group, on its PIPE sale of US$100 million of shares via a private placement to General Atlantic*
• (As UK securities counsel) HutchMed, a China-based, globally-focused healthcare group, on its Hong Kong public offering. It is one of the few companies with a dual triple listing on Nasdaq and AIM*
• Durable Capital Partners LP on its £110 million PIPE investment into Abcam plc, a global leader in the supply of life science research tools*
• Learning Technologies Group, an integrated e-learning services and technologies provider, on its £85 million secondary cash-box placing on AIM to finance its acquisition of PeopleFluent*
• Tissue Regenix Group plc, the regenerative medical devices company, on its £40 million secondary placing on AIM to finance its acquisition of CellRight Technologies, a US regenerative medicine business*
• Numis Securities Limited on the AIM IPO of Diurnal Group, a spin out company from the University of Sheffield specialising in targeting patient needs in chronic endocrine (hormonal) diseases and a member of the IP Group portfolio of companies*
• Motif Bio plc, a clinical stage biopharmaceutical company, on its £19.4 million placing on AIM*
• ScS Group plc, one of the UK's largest retailers of upholstered furniture and floorings, on its IPO admission to premium listing and to trading on the main market of the London Stock Exchange*
• SDL plc, an international language translation services business, on its £36.2 million secondary placing on the main market of the London Stock Exchange to finance its acquisition from Donnelley Financial Solutions, Inc. of the business and assets (including the shares of certain entities in Luxembourg and Spain) of Donnelley Language Solutions*
• The Coca-Cola Company on the $3.15 billion transition of Anheuser-Busch Inbev's majority interest in Coca-Cola Bottling Africa*

*Matter handled prior to joining Latham